Company / SG&A Expense
Dare Bioscience, Inc. SG&A Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$9.2M
FY2025
5-year range
$8.4M / $12.1M
FY2021-FY2025
Trend
-24.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 7 years, ranging from $6M in FY2015 to $12M in FY2024.
Based on SEC 10-K filings.
$9M in FY2025 with a 10-year CAGR of +4.0%.
Improved from $11M to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +3.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- +4.0%
Key checks
Key Insights
- 3-year CAGR of +3.1%, indicating consistent growth.
- In FY2025, sg&a expense decreased 24.4% year-over-year.
- Peak sg&a expense was recorded in FY2024.
- Lowest sg&a expense in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.2M | -24.4% |
| FY2024 | $12.1M | +7.7% |
| FY2023 | $11.2M | +34.6% |
| FY2022 | $8.4M | -2.7% |
| FY2016 | $8.6M | +39.3% |
| FY2015 | $6.2M | -3.6% |
| FY2014 | $6.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026